Last reviewed · How we verify
NCT06477172
A Multi-site, Prospective, Observational Study of Autologous Hair Follicle Secretome (aHFS) as an Adjunct to Medical Aesthetic Procedures
trial in Post Procedural Erythema in 500 participants. Currently enrolling.
1 February 2027
Quick facts
| Lead sponsor | Acorn Biolabs Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 9 September 2024 |
| Primary completion | 1 February 2027 |
| Estimated completion | 1 February 2027 |
| Sites | 40 locations across United States, Canada |
Conditions studied
- Post Procedural Erythema — all drugs for Post Procedural Erythema →
Sponsor
Acorn Biolabs Inc. — full company profile →
Who can join
18 and older, any sex, with Post Procedural Erythema. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Post-Procedure Symptoms
Time frame: 1-7 days
Symptoms of redness, swelling, oozing, pain, tenderness, crusting, itching and discoloration will be measured using a 1-10 likert scale with 0 being best possible and 10 being worst imaginable. -
Downtime Questionnaire
Time frame: 1-7 days
Questionnaire asking what activities would they have done, if it were not for their face appearance. Date of end of downtime captured.
Sponsor's own description
Non-interventional, multi-site, prospective, open-label, observational, real-world study of autologous hair follicle secretome use.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06477172
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Acorn Biolabs Inc. trials
Trials by the same sponsor.
- NCT07227883 — Secretome Treatment for Facial Rejuvenation · EARLY_PHASE1 · recruiting
- NCT07107841 — Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site) · NA · recruiting
- NCT06336135 — Reduction in Symptoms After Laser Therapy With Acorn aHFS · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06477172 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Acorn Biolabs Inc.
- Last refreshed: 2 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06477172.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing